This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Amarin Pharma

Stocks in this article: AMRN AEZS KERX CTIC AGEN VNDA GSK

BOSTON ( TheStreet) -- Contrary to popular opinion, I am capable of saying something nice about biotech stocks. I'm not all doom and gloom. Don't believe me? Check this out:

"Adam, I recently bought some shares of Amarin (AMRN)," emails Santander S. "The stock is pretty cheap and it has two phase III studies for a fish oil drug that can address a big market. You seem not to like a lot of small biotech stocks, including ones that I do like, but maybe Amarin is a stock we can agree on. What do you think?"


I think we agree on Amarin. I like this stock. The company's lead drug is AMR 101, an ultra-purified form of the omega-3 fatty acid known as Ethyl EPA. Think of AMR 101 as medicinal-grade fish oil, which can be prescribed by doctors to treat patients with high levels of triglycerides.

> > Bull or Bear? Vote in Our Poll

I was skeptical when I first looked into the Amarin story because my knee-jerk reaction was to scoff at any company developing prescription-grade fish oil. What's the point? Why can't people interested in lowering their triglyceride levels and improving heart health simply buy cheap fish oil capsules at their local health food store?

Not all fish oils are the same, I learned. The stuff you can buy retail doesn't contain pure omega-3s. By comparison, the manufacturing process Amarin uses for AMR 101 produces a drug that is almost pure ethyl EPA, which makes it more potent. And clinical studies have already demonstrated that higher levels of Omega-3s produce larger, more clinically significant reductions in triglyceride levels.

FDA Calendar
14 Biotech Stocks Facing FDA Approval

More comforting is the fact that GlaxoSmithKline (GSK - Get Report) paid $1.6 billion in 2007 to purchase privately held Reliant Pharmaceuticals, makers of the first prescription fish-oil drug. That drug, Lovaza, generates more than $1 billion in worldwide annual sales for Glaxo, including more than $700 million annually in the U.S.

Who knew that fish oil could be such a big deal?

Amarin is conducting two placebo-controlled, double-blinded phase III studies of AMR 101, both operating under Special Protocol Assessments from the U.S. Food and Drug Administration. The MARINE study is enrolling 240 patients with very high triglyceride levels (>500 mg/dl). The second study, ANCHOR, is enrolling 650 patients with mixed lipid levels (triglycerides >200 mg/dl) who are also taking a statin to lower cholesterol.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs